QuidelOrtho Corp (QDEL): Total Liabilities
$3.85B
As of 2025-12-28
$3.94B
As of 2026-06-28
-0.6%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-28 | $3.85B | +11.9% | 2026-02-19, Balance as of period end |
| 2024-12-29 | $3.44B | -3.3% | 2026-02-19, Balance as of period end |
| 2023-12-31 | $3.56B | -9.3% | 2025-02-27, Balance as of period end |
| 2023-01-01, Fiscal 2022 | $3.92B | +682.7% | 2024-08-01, Balance as of period end |
| 2022-01-02, Fiscal 2021 | $501.00M | n/a | 2023-02-23, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | 2025-12-28 | $3.85B | +11.9% |
| Idexx Laboratories Inc (IDXX) | 2025-12-31 | $1.75B | +2.8% |
| Lantheus Holdings, Inc. (LNTH) | 2025-12-31 | $1.14B | +27.5% |
| Neogen Corp (NEOG) | 2026-05-31 | $1.25B | -8.7% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $338.60M | +3.7% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $170.73M | -46.5% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $34.81M | -4.3% |
| Immucell Corp (ICCC) | 2025-12-31 | $15.48M | -12.0% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $12.39M | +53.8% |
Compare QDEL, IDXX, LNTH, NEOG side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗